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Summary In a prospective randomised study 68 patients with limited small cell bronchogenic carcinoma
were assigned to induction treatment with combined alternating non-cross-resistant chemotherapy plus split
course radiotherapy without (NM) or with (M) subsequent maintenance therapy. Induction chemotherapy
consisted of cisplatinum and VP16213 q. 3 weeks followed by cyclophosphamide, vincristine and methotrexate
(CVM)q. 4 weeks. Three courses of this 7-week chemotherapy programme were given. Radiotherapy to the
primary lesion of 25Gy in 13 fractions was given after each of the first and second courses of chemotherapy.
Those in complete remission following the induction phase received prophylactic cranial irradiation. Those
assigned to maintenance received a further six cycles of CVM after induction. The overall survival of patients
randomised to maintenance therapy was significantly inferior to that of those randomised to no maintenance
therapy (median survival NM 19.2 vs M 14.1 months, P=0.05 log rank). Among patients achieving a
complete remission of disease on induction therapy those receiving maintenance also showed a trend towards
inferior survival (median survival NM26.8 vs 18.0 months, P=0.06 log rank). Deaths in each group of
patients were predominantly due to tumour progression. The results do not support the use of maintenance
chemotherapy after the use of intensive combined therapy induction programmes in the management of
limited small cell bronchogenic carcinoma.
The outcome of treatment of patients with small cell lung
cancer remains guarded. Even when the disease is initially of
limited extent, median survival is approximately 12-15
months with less than 10% of patients achieving long-term
disease-free survival (Bunn et al., 1987; Osterlind et al.,
1986). The contribution of maintenance chemotherapy to the
outcome in those patients who achieve some degree of
disease control following initial treatment is unclear, as is its
role in the management of complete responders who may
have the potential for long-term survival (Bleechen et al.,
1986; Einhorn et al., 1987; Ettinger et al., 1987; Harper et
al., 1987; Splinter et al., 1986; Woods and Levi, 1984).
We report the results of a controlled clinical trial in which
patients achieving complete remission, partial remission or
disease stabilisation following initial treatment were
randomly assigned to maintenance chemotherapy or to
observation. The findings indicate that the maintenance
chemotherapy used made no positive contribution to the
outcome and was, in this small study, associated with a
decreased survival in the group of patients so treated.
Methods
Patient selection
Patients were entered into the study between March 1981
and October 1985 from three University teaching hospitals in
Western Australia. Eligible patients were 70 years of age or
younger, had histologically or cytologically proven small cell
lung cancer and had received no previous chemotherapy or
radiotherapy. All had limited disease defined as disease
clinically confined to one lung, mediastinum and ipsilateral
supraclavicular nodes at the time of initial staging.
Staging procedures consisted of clinical examination,
complete blood count and standard biochemical profile. PA
and lateral chest X-ray, bronchoscopy, radionuclide liver
scan, bone scan and bone marrow aspiration and trephine.
Only those patients with any neurological symptoms or signs
has a cerebral CT scan performed, but this examination was
not undertaken as part of the initial staging on all patients.
Patients with radiologically evident pleural effusions were
excluded irrespective of the cytological findings in aspirated
fluid.
At the time of entry into the study, patients were
randomly assigned to one of two treatment arms,
maintenance or non-maintenance. Each arm consisted of
initial treatment with three courses of alternating cycles of
non-cross-resistant chemotherapy. After the first and second
course, patients received radiotherapy to the primary site,
mediastinum and, if involved, ipsilateral supraclavicular
lymph nodes. Following this initial treatment, which lasted
approximately 26 weeks, patients were restaged. Restaging
involved repeating all the staging procedures including
bronchoscopy and bronchoscopic biopsy. In addition, all
patients found to be otherwise in complete remission had a
cerebral CAT scan. Those in complete remission, partial
remission or with stable disease who had been assigned to
maintenance therapy then received a further six cycles of
chemotherapy (Figure 1). Prophylactic cranial radiotherapy
was given to all those in complete remission.
The management of those whose disease progressed during
initial treatment, who relapsed following initial complete and
partial remission, or who had stable disease was not
specified in the protocol and was at the discretion of the
clinician.
Patients gave written informed consent and the study was
approved by the Committee for Human Rights of the
University of Western Australia.
Induction therapy
The initial combined chemotherapy and split course radio-
therapy induction schedule was identical for each arm of the
study (Figure 1).
Chemotherapy
Initial chemotherapy consisted of cisplatinum 60mgm-2 i.v.
day 1 and VP 16213 120mgm-2 i.v. days 1, 3 and 5
(DDPVP) followed on the twenty-second day by
cyclophosphamide 400mgm-2 orally days 22-26, vincristine
1.4mgm-2 i.v. day 22 and methotrexate 30mgm-2 day 43
i.v. (CVM).
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Figure 1 Trial design.
In all, three courses of this 7-week chemotherapy
programme were given. The first moiety of thoracic radio-
therapy (see below) began on day 50 of the first course of
chemotherapy and was complete in 21 weeks (Figure 1).
The second course of chemotherapy began immediately after
the first moiety of radiotherapy was completed. The second
moiety of radiotherapy began on day 50 of the second
course of chemotherapy and the third course of chemo-
therapy began immediately following completion of the
thoracic radiotherapy.
Those assigned to maintenance chemotherapy received a
further six cycles of CVM at 4 weekly intervals beginning
immediately after restaging.
Drug doses were modified because of haematological
toxicity on the basis of white cell and platelet counts on the
day of therapy. If the white cell count was > 3 x 109 1 and
the platelet count was 100 x 109 1- 1, full doses of cyclo-
phosphamide, VP 16213 and methotrexate were given. Doses
were reduced to 75% of calculated dose for total white cell
counts of 2.5-2.9 x 1091- 1 and platelet counts of 75-
99 x 1091-1. Treatment was delayed until counts reached
appropriate levels if the white cell count was <2.5 x 109 1-
or platelet count was <75 x 19 -1.
Vincristine was given in full dose calculated for surface
area. Vincristine and cisplatinum dosages were not modified
because of myelosuppression but administration was delayed
if myelosuppression resulted in delay in administration of
other drugs. Delivery of the radiotherapy induction regimen
was delayed until the white cell count was >3.0 x 109 -1
and the platelet count was >100 x 1091-1. Myelosuppression
did not delay delivery of prophylactic cranial irradiation.
Modifications were also made for mucosal toxicity, renal
toxicity, neurotoxicity and auditory toxicity. In the presence
of severe cyclophosphamide cystitis, chlorambucil was
substituted for cyclophosphamide.
Radiotherapy
Radiotherapy was directed to the primary lesion,
mediastinum and, if clinically involved, ipsilateral
supraclavicular nodes. Megavoltage beams were used. The
area of the field below the clavicles was not to exceed
150cm2. A dose of 25Gy in 13 fractions over 21 weeks was
given after the first and second course of chemotherapy,
giving a total dose of 50Gy divided into two equal moieties
of 25 Gy, 7 weeks apart. The method of delivery of the first
moiety was by parallel opposed ports. The second was given
by a similar method or by a three-field technique at the
radiotherapist's discretion. Treatment of the supraclavicular
fossa involved a single anterior field in continuity with the
mediastinal field using similar parameters of dose and
delivery. A posterior parallel field with shielding was?
optional.
Prophylactic cranial irradiation in a dose of 30Gy in 15
fractions over 3 weeks by lateral parallel opposed fields to
encompass the entire intracranial contents was given to all
patients who were in complete remission after restaging at
the end of initial treatment. In those receiving maintenance
chemotherapy prophylactic cranial irradiation and main-
tenance therapy were given concomitantly.
Response criteria and analysis
Standard response criteria (Miller et al., 1981) were used
except that patients were only assessed for complete response
at the end of initial therapy and restaging which included
bronchoscopy with biopsy or bronchial brushings.
Patients who appeared clinically free of disease during
initial therapy but whose disease progressed before restaging
were not considered to be complete responders.
Survival time was measured from the date of
randomisation until death or last follow-up. Progression-free
survival was measured from the date of randomisation until
progression or death without progression. Patients who died
without recurrence or progression of tumour were not
censored from the analysis of progression-free survival, i.e.
they were assumed to have died of tumour despite no
evidence of progression or recurrence before death.
Toxicity related to treatment was graded according to
WHO criteria (Miller et al., 1981).
Survival curves were prepared by the method of Kaplan
and Meier and the curves compared using the log rank test
Kaplan & Meier, 1958; Peto et al., 1977). The effect of the
prognostic variables, maintenace, sex, age, tumour size and
location on survival time and time to first progression were
analysed using Cox's proportional hazards models (Cox,
1972). Confidence intervals for the median survival were
calculated using the method of Brookmeyer and Crowley
(1982).
Results
Sixty-eight patients were entered into the study and
randomised. Two were found to be ineligible, one with non-
small cell lung cancer and one with a past history of
malignant melanoma. The clinical characteristics of the 66
eligible patients are shown in Table I. An estimate of th,e
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Table I Patient characteristics
Non-maintenance Maintenance
Randomised 33 35
Ineligible 1 1
Eligible 32 34
Sex Male 21 27
Female 11 7
Site Central 26 31
Peripheral 6 3
Volume measurable 22 22
Mean volume (cm3) 71.6 63.0
Age median (range) 62(41-70) 60(39-70)
Performance status 0 15 16
1 14 15
2 3 3
volume of tumour from measurements on chest X-rays was
possible in 44 patients.
Randomisation achieved a satisfactory balance of those
patients assigned to maintenance (M) and non-maintenance
(NM) arms with respect to age, sex, site of primary tumour,
tumour volume and patient performance status.
The first patient was entered on study on 10 March 1981
and the last on 30 October 1985. The median time from
entry at analysis was 44 months, at which time 51 (77%) of
the patients had died.
Of the 66 eligible patients, 39 (59%) achieved a complete
remission of disease following the initial therapy. Twenty of
these had been randomised to no further treatment and 19 to
the maintenance arm of the study.
The absolute survival of treated patients is shown in
Table II and Figure 2. Those assigned to maintenance
therapy had a less favourable outcome than those assigned
to no maintenance therapy (median M 14.1 months versus
NM 19.2 months, P=0.05 log rank). Age, sex, site of
primary tumour and size (> or < than the mean) did not
significantly influence survival, with only the presence or
absence of maintenance therapy being the significant factor
in a Cox regression analysis. The trend towards an inferior
survival for those assigned to maintenance therapy was also
seen in the 39 patients achieving complete remission (median
M 18.0 months versus NM 26.8 months) although this
difference did not reach statistical significance (P=0.06 log
rank).
The progression-free survival of those assigned to
maintenance therapy was also inferior (median M 12.9
months versus NM 16.3 months) but this difference was not
statistically significant (P=0.48 log rank).
Nineteen of the 34 eligible patients randomised to the
maintenance arm were alive without evidence of disease
progression after initial therapy and therefore were able to
receive the maintenance therapy. All were in complete
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Survival time (months)
Number at risk
No maint. 32 22 10 5 3 1 0
Maint. 34 19 6 2 2 1 0
...........
Figure 2 Survival time by treatment group. No maintenance, ;
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remission after the initial 26 weeks of therapy and restaging.
None was still in PR or NC status. Twenty of the 32
randomised to no maintenance were in complete remission
after the induction therapy.
Twenty-six of the 39 complete responders have died. The
causes of death in all complete responders were examined to
detect any influence of toxicity on the outcome in patients
receiving maintenance therapy. There were no deaths due to
toxicity. Tumour recurrence was the cause in 20 cases.
Deaths without recurrence occurred in four patients
randomised to maintenance therapy. Only one of these
patients was receiving maintenance therapy at the time of
death. Two patients in the non-maintenance arm died while
in complete remission with no evidence of disease recurrence.
Table III shows the sites of the first disease progression in
all eligible patients. The first site of disease failure was
outside the irradiated field in most patients.
Primary relapse in the central nervous system following
prophylactic cranical irradiation occurred in only two
patients. In one patient the site of first relapse was
meningeal. Another relapsed simultaneously in brain and
lung.
The toxicity experienced during initial therapy is shown in
Table IV. Haematological and gastrointestinal toxicity were
predominant. Forty-six per cent of patients experienced
WBC drop to <2 x 1091- on at least one occasion.
One patient developed septicaemia and pneumonia with
hypotension while neutropenic, but recovered fully with
treatment. Eight others had a respiratory tract infection
requiring treatment at some time during induction therapy.
A further four had fever of uncertain origin, two with
Table II Survival and progression-free survival
Evaluable Median 95% confidence Significance
patients (months) interval median (log rank)
Survival
Total eligible 66 15.8 12.4-19.2
NM 32 19.2 12.4-31.4 P poo5
M 34 14.1 10.1-17.0
Complete responders 39 25.0 17.0-27.9
NM 19 26.8 19.2-65.5
P -
M 20 18.0 14.6-25.0 P=0.06
Progression-free survival
Total eligible 66 15.6 11.8-17.1
NM 32 16.3 11.2-22.3 P-0.48
M 34 12.9 9.4-18.0
Complete responders 39 20.5 16.2-27.9
NM 19 27.8 16.2-65.5 P-0.55 M 20 17.1 12.9-61.0 _0.416 M.J. BYRNE et al.
Table III Initial site of progression
NM M Total(%)
Irradiated field alone 5 3 8(12)
Outside irradiated field alone 16 12 28(43)
Inside and outside irradiated field 1 5 6(9)
Not evaluable 1 3 4(6)
No progression 9 11 20(30)
Total 32 34 66
Table IV Worst toxicity overall: eligible 66
WHO grade (%)
2 3 4
Hb 10(15) 7(10) 1(2)
WBC 20(30) 25(38) 5(8)
Platelets 4(6) 5(8) 4(6)
Infection 13(20) - 1(2)
Nausea/vomiting 1(2) 48(73) 9(13)
Mucositis 8(12) 1(2) -
Urinary 1(2)
Oesophagitis 4(6) 1(2)
Neurological 8(12) -
Auditory 3(5) -
accompanying leucopenia. One patient had a mild urinary
tract infection. Twelve per cent of patients had a drop in
haemoglobin to below 8.0gdl-P while 14% had at least one
episode of thrombocytopenia (less than 50 x 1091-1). Eighty-
six per cent of patients experienced grade 3 or 4 vomiting
despite prophylactic high dose metaclopramide therapy
during treatment with cisplatinum. One patient experienced
severe oesophagitis and another severe oral mucositis but
otherwise toxicity was generally mild.
The objective toxicity of maintenance therapy was less.
Five patients developed leukopenia of, <2 x 1091-1 on at
least one occasion. There were no serious infections. Grade 3
gastrointestinal toxicity occurred in only 18% of cases. Three
patients, however, refused maintenace therapy and six
withdrew before the six cycles were complete.
The intensity of chemotherapy given during the induction
phase to those randomised to each arm of the study was
calculated to detect possible imbalance in the groups. Figure
3 shows the percentage of patients who received 80% or
more of the ideal scheduled dose for each of the three
induction courses. No imbalance was detected. Those
randomised to receive maintenance therapy received the
same intensity of induction chemotherapy as those
randomised to no maintenance.
;30- 4 f%f^
Discussion
In this study patients randomised to maintenance therapy
had a significantly inferior survival to that of those receiving
induction therapy alone. Deaths in the maintenace treated
group were predominantly due to uncontrolled small cell
cancer and not to toxicity of the maintenance therapy. While
other studies have shown limited -or no advantage to
maintenance chemotherapy, a significant adverse effect has
not been seen (Table V).
The median survival of 15.8 months for all treated patients
and 25 months for those who achieved complete remission is
comparable to that of other groups of patients with limited
small cell cancer so treated (Bunn et al., 1987). Those
managed with the induction treatment programme alone,
however, had a median survival of 19.2 months and 48%
were relapse-free at 2 years, which is superior to that
generally reported for such patients.
Had maintenance therapy merely failed to improve the
results achieved by the initial therapy, it may have indicated
that median survivals of 18-20 months are close to the limits
of what can be achieved with current conventional chemo-
therapy and radiotherapy and that prolonging such
treatment will not add significantly to the result. The
apparent detrimental effect of maintenance therapy is not
easily explained on this basis in the absence of evidence of
toxicity leading to premature deaths.
The delivery of maintenance chemotherapy may have
influenced the amount of chemotherapy given after relapse
as relapse therapy was not specified in the protocol. If those
who had not received maintenance therapy were able to
receive more chemotherapy after relapse than those who
had, this may have had a favourable influence on the
survival of the non-maintenance group. To examine this
possibility, the total drug dose and dose intensity of drug
delivery after relapse was assessed in all patients who
achieved complete remission. There were no significant
differences between the groups. The reason for the
significantly inferior survival of those randomised to
maintenance therapy is therefore unclear.
Given the small numbers of patients accrued to this study,
the absence of a clear explanation for the inferior survival of
the maintenance group and the marginal significance of the
difference, it is probably wisest to interpret the data as
showing no benefit for maintenance chemotherapy. Viewed
in this way the results are complementary to those of other
larger studies addressing this question (Table V).
Progression outside the irradiated field was the site of
primary failure in 49% of cases, indicating that failure of
chemotherapy to control metastases remains the major
weakness of combined modality therapy. This study provides
no encouragement that prolonging treatment with
maintenance regimens of the type used will produce
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Figure 3 Percentage of patients receiving >80% of prescribed dose of drug for each course of chemotherapy. CP, Cisplatinum;
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Table V Maintenance chemotherapy in small cell lung cancer, randomised studies
Author Disease extent Treatment Survival
CAV x 10
Cisplat VP16 x 4 PR 9 overall median 50wks
Woods et al. LD,ED +DXRT CR
+PCI L zero M vsNM,n.s.
CVMVP16x6
Bleehen et al. LD,ED CVM VP16 x 6 PR 9 overall median 57wks
+DXRT,LD CR
zero M vsNM,n.s.
CAVP16 x 7
CAVP16 x 5 NC overall median 33-41 wks
Splinter et al. LD,ED No DXRT PR
+PCI CR
zero M vsNM, n.s.
CVVP16x4
Harper et al. LD,ED CVVP16 x 4 LDM48wks vs NM42wksn.s.
zero ED M 34wks vsNM28 wks n.s.
CAV/HMVP16 x 6-8 F Induction CR M 75wksvsNM 61 wksn.s.
Ettinger et al. ED CR
CAV x6-8 L zero
CisplatVP16 x 2
Einhorn et al. LD CAV x 6 PR 9 PR+CRM98wksvsNM67wks
+DXRT CR
<zero P =0.009
CisplatVP16/CVM x 3 NC Total M60wk vsNM 81 wk
+DXRT PR - CVMx6
+PCI CR P =0.05
Byrne et al. LD
(present study) CisplatVP16/CVM x 3 NC
+DXRT PR - zero
+PCI CM
LD, limited disease; ED, extensive disease; Cisplat, cisplatinum; VP16, VP16213; C, cyclophosphamide; V, vincristine;
A, adriamycin; M, methotrexate; H, hexamethylmelamine; DXRT, thoracic irradiation; PCI, prophylactic cranial irradiation.
significant benefit. Other such studies (Table V) have also
shown little or no evidence of benefit. It seems unlikely then
that protocols relying on increasing the duration of chemo-
therapy with currently available agents will produce a
quantum change in control outside of the irradiated field.
Those in which a single combination is used during
induction may improve outcome by incorporating a non-
cross-resistant regimen as consolidation (Einhorn et al.,
1987), but if alternating non-cross-resistant regimens are
used during induction no extra benefit accrues with
prolonged therapy.
In 12% of our patients the site of first progression was
within the irradiated field. This is a somewhat lower figure
than reported in trials of similar design (Perez et al., 1984;
Perry et al., 1987). As the toxicity of the radiotherapy dose
and schedule used was low, the prospect exists for a small
improvement in local control by modification of the radio-
therapy programme.
Of the patients who achieved complete remission only two
relapsed in the central nervous system, implying that
prophylactic cranial irradiation as delivered provides
sufficient protection against central nervous system relapse.
If the overall treatment becomes more successful in the
future late central nervous system relapse may become more
prominent.
The basic strategy of the induction regimen of alternating
cycles of non-cross-resistant chemotherapy with split course
radiotherapy and prophylactic cranial irradiation for those in
complete remission has produced a complete remission rate
of 59% with 48% two-year disease-free survival in those not
receiving maintenance therapy. The changes to the dose and
scheduling of thoracic radiotherapy may produce an
incremental improvement but a significant improvement in
the degree of control ofmetastatic disease will be required to
improve long-term outlook. It seems unlikely that
maintenance chemotherapy will produce such benefit.
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